For the development of novel monoclonal antibody-based therapeutics for oncology and autoimmune diseases, Medarex, Inc. (Nasdaq: MEDX) and Compugen Ltd. (TLV: CGEN) have entered into a collaborative agreement.
The terms of agreement include:
- Medarex and Compugen will share discovery, development and commercialization responsibilities on antibody-based therapeutics resulting from this collaboration, and share revenues generated from the sale of such therapeutic products.
- Compugen expects to utilize its proprietary antibody-target discovery engine to identify novel drug targets.
- Medarex will develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System®.
- Compugen may independently pursue diagnostic applications involving certain antibodies and targets.
Comment Preview